Advertisement
UK markets closed
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • FTSE 250

    19,601.98
    -117.39 (-0.60%)
     
  • AIM

    752.90
    -1.79 (-0.24%)
     
  • GBP/EUR

    1.1651
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2492
    +0.0030 (+0.24%)
     
  • Bitcoin GBP

    51,247.24
    -473.71 (-0.92%)
     
  • CMC Crypto 200

    1,381.31
    -1.26 (-0.09%)
     
  • S&P 500

    5,016.81
    -54.82 (-1.08%)
     
  • DOW

    37,895.19
    -565.73 (-1.47%)
     
  • CRUDE OIL

    82.45
    -0.36 (-0.43%)
     
  • GOLD FUTURES

    2,341.70
    +3.30 (+0.14%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • CAC 40

    8,016.65
    -75.21 (-0.93%)
     

Possible Bearish Signals With Moderna Insiders Disposing Stock \

The fact that multiple Moderna, Inc. (NASDAQ:MRNA) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Moderna

The Last 12 Months Of Insider Transactions At Moderna

In the last twelve months, the biggest single sale by an insider was when the CEO & Director, Stephane Bancel, sold US$1.6m worth of shares at a price of US$160 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$132. So it may not tell us anything about how insiders feel about the current share price.

ADVERTISEMENT

Insiders in Moderna didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Does Moderna Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Moderna insiders own about US$4.9b worth of shares (which is 9.7% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The Moderna Insider Transactions Indicate?

The fact that there have been no Moderna insider transactions recently certainly doesn't bother us. While we feel good about high insider ownership of Moderna, we can't say the same about the selling of shares. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Be aware that Moderna is showing 2 warning signs in our investment analysis, and 1 of those is significant...

But note: Moderna may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here